Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

97 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of molnupiravir and sotrovimab in Japanese dialysis patients with COVID-19 in clinical practice during the Omicron (BA.1 and BA.2) pandemic.
Kikuchi K, Nangaku M, Ryuzaki M, Yamakawa T, Ota Y, Hanafusa N, Sakai K, Kanno Y, Ando R, Shinoda T, Wakino S, Nakamoto H, Takemoto Y, Akizawa T; COVID-19 Task Force Committee of the Japanese Association of Dialysis Physicians, the Japanese Society for Dialysis Therapy, and the Japanese Society of Nephrology. Kikuchi K, et al. Among authors: ryuzaki m. Ther Apher Dial. 2023 Dec;27(6):1064-1069. doi: 10.1111/1744-9987.14033. Epub 2023 Jul 3. Ther Apher Dial. 2023. PMID: 37395555
Estimating immunity with mathematical models for SARS-CoV-2 after COVID-19 vaccination.
Uwamino Y, Nagashima K, Yoshifuji A, Suga S, Nagao M, Fujisawa T, Ryuzaki M, Takemoto Y, Namkoong H, Wakui M, Matsushita H, Hasegawa N, Sato Y, Murata M. Uwamino Y, et al. Among authors: ryuzaki m. NPJ Vaccines. 2023 Mar 6;8(1):33. doi: 10.1038/s41541-023-00626-w. NPJ Vaccines. 2023. PMID: 36878929 Free PMC article.
Changes in erythropoiesis-stimulating agent responsiveness after transfer to combined therapy with peritoneal dialysis and hemodialysis for patients on peritoneal dialysis: A prospective multicenter study in Japan.
Maruyama Y, Yokoyama K, Higuchi C, Sanaka T, Tanaka Y, Sakai K, Kanno Y, Ryuzaki M, Sakurada T, Hosoya T, Nakayama M; EARTH (Evaluation of the Adequacy of Renal replacement THerapy) study group. Maruyama Y, et al. Among authors: ryuzaki m. Ther Apher Dial. 2023 Aug;27(4):735-741. doi: 10.1111/1744-9987.13981. Epub 2023 Mar 22. Ther Apher Dial. 2023. PMID: 36897071
T-Cell Response and Antibody Production Induced by the COVID-19 Booster Vaccine in Japanese Chronic Kidney Disease Patients Treated with Hemodialysis.
Yoshifuji A, Toda M, Ryuzaki M, Oyama E, Kikuchi K, Kawai T, Sakai K, Koinuma M, Katayama K, Yokoyama T, Uehara Y, Ohmagari N, Kanno Y, Kon H, Shinoda T, Takano Y, Tanaka J, Hora K, Nakazawa Y, Hasegawa N, Hanafusa N, Hinoshita F, Morikane K, Wakino S, Nakamoto H, Takemoto Y. Yoshifuji A, et al. Among authors: ryuzaki m. Vaccines (Basel). 2023 Mar 14;11(3):653. doi: 10.3390/vaccines11030653. Vaccines (Basel). 2023. PMID: 36992238 Free PMC article.
Cellular and humoral immune responses to COVID-19 booster vaccination in Japanese dialysis patients.
Yoshifuji A, Toda M, Oyama E, Nakayama T, Mise-Omata S, Kikuchi K, Yoshizawa M, Kato N, Wakai H, Koibuchi K, Morimoto K, Uwamino Y, Namkoong H, Shibata A, Wakabayashi K, Fujino M, Komatsu M, Mochizuki N, Kondo N, Yoshimura A, Hasegawa N, Ryuzaki M. Yoshifuji A, et al. Among authors: ryuzaki m. Clin Exp Nephrol. 2024 Jul;28(7):674-682. doi: 10.1007/s10157-024-02477-8. Epub 2024 Mar 8. Clin Exp Nephrol. 2024. PMID: 38457030
Ultra-Low-Dose Contrast Using Transluminal Renal Angioplasty: The ULTRA Study.
Kawano M, Suzuki K, Fujimura N, Endo A, Kato A, Fujii K, Komatsu M, Takahashi T, Ryuzaki M, Harada H. Kawano M, et al. Among authors: ryuzaki m. Vasc Endovascular Surg. 2023 May;57(4):324-330. doi: 10.1177/15385744221145867. Epub 2022 Dec 12. Vasc Endovascular Surg. 2023. PMID: 36509460
97 results